← Leaderboards
David Larwood
Valley Fever Solutions, Inc.
$3,652,445
Attributed
$5,152,362
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2010–18$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$5,152,362 · 2
By mechanism
RC3$2,999,834 · 1
U01$2,152,528 · 1
Top collaborators
- John N Galgiani1 shared
Others in their field
Top investigators on “Inhibitor/Antagonist”
- John M Lachin · George Washington University$117,867,649
- David M Nathan · Massachusetts Institute Of Technology$117,867,649
- Randall J Bateman · Washington University$110,978,751
- David Heimbrook · Leidos Biomedical Research, Inc.$72,139,282
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Walter John Curran · Thomas Jefferson University$32,790,605
Research focus
Inhibitor/AntagonistPersonsFungusInfectionMycosesPathway InteractionsDoseEnrollmentCoccidioidomycosisGeneticMedical AttentionModificationNikkomycinNikkomycin XBusinessesClinical TrialsAntifungal AgentsEarly TreatmentCell WallArizonaChitin SynthaseFutureManufacturing ProcessPharmaceutical Preparations
Grant awards (6)
Nikkomycin Z treatment of primary pneumonia due to Coccidioides$190,126
U01 · FY2018 · AI · contact PI
Nikkomycin Z treatment of primary pneumonia due to Coccidioides$859,330
U01 · FY2016 · AI · contact PI
Nikkomycin Z treatment of primary pneumonia due to Coccidioides$864,797
U01 · FY2015 · AI · contact PI
Nikkomycin Z treatment of primary pneumonia due to Coccidioides$26,816
U01 · FY2015 · AI · contact PI
Nikkomycin Z treatment of primary pneumonia due to Coccidioides$211,459
U01 · FY2014 · AI · contact PI
Nikkomycin Z treatment of early coccidioidal pneumonia: Phase II clinical trial$2,999,834
RC3 · FY2010 · MD